Abstract: The present invention is directed to a cytokine fusion protein comprising an immunocyte targeting domain and a cytokine function domain capable of specifically inducing the proliferation and/or activation of immunocytes. Specifically, the present invention is directed to a fusion protein that specifically delivers cytokines (e.g., IL-2 or IL-15) to exhausted immunocytes (e.g., exhausted T cells) in tumors to induce and increase the activation of the immunocytes. The fusion protein of the present invention can deliver a cytokine, which promotes the proliferation or activation of the immunocyte, selectively to the effector T cells, etc. in the tumor microenvironment, thereby inducing strong immune enhancement and anti-cancer response in tumors and significantly reducing systemic toxicity or side effects of cytokines through the unique structure of the cytokine function domain.

Abstract: The present invention relates to a stable liquid pharmaceutical formulation of a trametinib compound. According to the present invention, provided is a stable liquid pharmaceutical formulation suitable for oral administration, the stable liquid pharmaceutical formulation comprising: trametinib or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable solubilizing agent. The liquid pharmaceutical formulation according to the present invention can be stored at room temperature, is stable even when stored for a long period of time, and can exhibit excellent dissolution characteristics upon administration, even when confronted with changes in the environment inside the gastrointestinal tract, and thus can improve drug absorption.

Abstract: The present disclosure is directed to a protein binding agent, or an antibody or an antigen-binding fragment thereof, which binds to a programmed death-1 (PD-1) protein. The present disclosure further provides a polynucleotide sequence encoding the protein binding agent, the antibody or the antigen-binding fragment thereof, a vector comprising the polynucleotide sequence, or a host cell comprising the vector. Also, the present disclosure provides a pharmaceutical composition or a kit, which comprises the protein binding agent, the antibody or the antigen-binding fragment thereof.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: The present invention relates to: a method for evaluating response to treatment using a MEK 1/2 inhibitor in an individual diagnosed with a neurodegenerative disease; and a composition to be used for the method. Particularly, the method of the present invention comprises measuring, in a biological sample obtained from the individual with a neurodegenerative disease, the concentration of at least one biomarker selected from the group consisting of osteopontin, synaptotagmin-1, apolipoprotein-E, cathepsin B, HLA-DOB (HLA class II histocompatibility antigen, DO beta chain), and neurofilament light chain. According to the present invention, response to the MEK 1/2 inhibitor in the individual diagnosed with a neurodegenerative disease is monitored, and it is thereby possible to obtain useful information for managing the individual, such as determining the possibility of a treatment effect early on and determining whether to continue drug treatment and whether the amount needs to be adjusted.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.

Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.